Does Publishing Knowledge Help Win Business?

Claims in this piece are observable and methodological — no client or benchmark data used.

It’s a fair and slightly skeptical question, and most CDMO commercial leaders have asked some version of it. Publishing technical content takes time your specialists don’t have. It rarely produces an obvious, traceable enquiry. And the pharmaceutical business has always run on relationships and qualification, not on articles. So the honest question is worth asking plainly: does publishing knowledge actually help win business, or is it just activity that feels productive?

The honest answer has two parts, and the order matters.

First, what publishing knowledge does not do. It does not, on its own, win business. It does not replace technical evaluation, audits, quality agreements, or the commercial relationship. It does not guarantee enquiries, and no one can promise that a published article produces a specific deal. Anyone claiming a direct, guaranteed line from “publish content” to “win contract” is overselling it. The parent article, Why Published Expertise Is Becoming a Discovery Advantage, is careful about this: published expertise is evidence, not a purchase of an outcome.

Second, what it does do — and this is the part that has changed. It affects whether you are in the consideration set at all, at a stage that now often happens before you know a buyer exists.

Where publishing knowledge actually operates

To see whether publishing helps win business, you have to be precise about where in the buying process it operates. It does not operate at the negotiation, or the audit, or the technical review. It operates earlier — at the discovery and early-research stage, before the buyer has made contact.

At that stage, a buyer researching partners, increasingly with an AI assistant, is working entirely from what is publicly discoverable. They are trying to establish who is relevant and credible enough to investigate further. Published knowledge — a genuine, specific explanation of a capability you actually hold — is exactly the kind of evidence that lets an outsider make that judgement in your favour. Its absence is exactly what leaves a capable manufacturer looking generic or invisible.

So the accurate way to state the commercial value is not “publishing knowledge wins business.” It is: publishing genuine knowledge influences whether you are considered — and you cannot win business you were never in the running for. That is a narrower claim, and a defensible one.

Why the effect is hard to measure — and why that doesn’t mean it isn’t real

Part of the skepticism comes from a measurement problem. The value of published knowledge shows up as an absence of a loss you never see: the enquiry that reaches you because a buyer could establish your capability, versus the one that quietly went elsewhere because they couldn’t. You see the enquiries that arrive. You do not see the shortlists you were left off, or why.

This is genuinely difficult to attribute, and it would be dishonest to pretend otherwise. A published article rarely comes with a clean, traceable path to a signed contract. But difficulty of measurement is not evidence of no effect. The mechanism is observable even where the revenue attribution isn’t: you can watch what an AI assistant or a new researcher can establish about your company, and you can see the difference between a capability that is published clearly and one that isn’t.

What kind of published knowledge actually helps

Not all publishing is equal, and this is where the skeptical question is partly right — a great deal of published pharmaceutical content genuinely does not help win business, because it publishes no real knowledge. Generic “committed to quality and innovation” pages, undifferentiated capability lists, and marketing language give an outsider nothing specific to establish.

What helps is narrower:

• Genuine, specific expertise — a real explanation of a capability you hold, at a level of specificity a technically competent buyer would recognise as substantive, not promotional.
• Knowledge tied to a real buyer need — content that answers the questions a buyer in your segment actually asks, rather than the topics you find easiest to write about.
• Accurate and current — knowledge published once and left to drift becomes misleading rather than helpful.
• Consistent with the rest of your public record — so it reinforces a coherent picture rather than adding another conflicting account.

The test is not “did we publish something.” It is “could a stranger, or the AI assistant helping them, establish a genuine, specific reason to consider us from what we published?”

A way to observe it for yourself

You don’t have to take the mechanism on faith. Take one capability where you have genuine depth but have published little. Then ask ChatGPT, Gemini, Perplexity, Claude and Copilot a question a buyer in that area would ask — for example:

Which CDMOs can support complex technology transfer for sterile injectables into regulated markets, and what distinguishes them?

Notice what the assistants can and cannot establish about you. Then look at a capability you have explained clearly and publicly, and compare. The difference between what an outside system can say about your published capability versus your unpublished one is the effect this article is describing — visible directly, without needing to trace it to a specific deal. This is a reproducible observation, not proof of revenue impact, and results vary by platform, prompt and time.

The honest takeaway

Publishing knowledge does not win business in the way a sales conversation or a successful audit wins business. Claiming it does would be the kind of overstatement that erodes trust. But it does something that increasingly precedes all of that: it determines whether a buyer researching before contact can establish a genuine reason to consider you. In a market where more of that early research runs through public information and AI assistants, being unable to be established at the discovery stage is a quiet, unmeasured way to lose business you never knew you were competing for. That is why publishing genuine expertise is worth taking seriously — not as marketing, but as making sure your real capability is available to be found.

Emerivo helps pharmaceutical manufacturing and research organisations — TPMs, CMOs, CDMOs and CROs — make genuine capability establishable to buyers and AI assistants at the discovery stage. The AI Discovery Audit™ tests what AI assistants can currently establish about your organisation against realistic buyer questions — diagnostic, not a promise of rankings or recommendations. Read the parent cornerstone: Why Published Expertise Is Becoming a Discovery Advantage.

Frequently asked questions